Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, will announce its interim results for the six months ended 31 December 2024 on Tuesday, 11 March 2025.
Aptamer Group to publish interim results on Tuesday 11th March
- Written by: Amilia Stone
Find more news, interviews, share price & company profile here for:
Aptamer Group plc reports impressive interim results for H1 2025, highlighting revenue growth and strategic advancements in life sciences innovation.
Aptamer Group plc reports progress on key projects in its H1 2025 trading update, highlighting partnerships with Unilever and Alzheimer's biomarker validation.
Aptamer Group plc (LON: APTA) secures a £155,000 contract to develop Optimer® binders for a rare disease biopharma, boosting clinical trial capabilities.
Aptamer Group plc enhances its Scientific Advisory Board with three leading experts to drive innovation and commercialization in targeted therapy solutions.
Aptamer Group plc (LON: APTA) updates on strategic programs with Unilever, Neuro-Bio, AstraZeneca, enhancing their Optimer® technology potential.
Join Aptamer Group plc's webinar on Dec 12, 2024, at 6 PM GMT for insights and Q&A with CEO Dr. Arron Tolley and CSO Dr. David Bunka.
